5-phenethyl-1H-indole | 91459-41-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 5-phenethyl-1H-indole
• 英文别名: 5-(2-Phenylethyl)-1H-indole
• CAS: 91459-41-5
• 化学式: C₁₆H₁₅N
• 分子量: 221.302
• InChiKey: KATLDDATAPXCBT-UHFFFAOYSA-N

物化性质

• 熔点：
  75 °C
• 沸点：
  375.8±11.0 °C(Predicted)
• 密度：
  1.132±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  5-phenethyl-1H-indole 在 sodium acetate 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 、 水 、 甲苯 、 mineral oil 为溶剂， 反应 12.42h， 生成
  参考文献：
  名称：

  铑（III）催化的区域选择性直接C4烷基化和吲哚的C2环化反应：直接获得吲哚并吡啶酮

  摘要：

  通过使用可变的重氮酯开发了Rh III催化的吲哚衍生物的位点C4烷基化和C2环化。对重氮酯反应性的微调可以控制区域选择性，具有宽范围和官能团耐受性。已经建立了一种简单的方法来提供吲哚并吡啶酮支架。

  DOI：

  10.1002/ejoc.201701755
• 作为产物：
  描述：

  5-碘吲哚 在 palladium on activated charcoal 、 四(三苯基膦)钯 copper(l) iodide 、 氢气 、 三乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 43.0h， 生成 5-phenethyl-1H-indole
  参考文献：
  名称：

  Synthesis and biological evaluation of new dipyrrolo[3,4-a:3,4-c]carbazole-1,3,4,6-tetraones, substituted with various saturated and unsaturated side chains via palladium catalyzed cross-coupling reactions

  摘要：

  The syntheses of a series of dipyrrolo[3,4-a:3,4-c]carbazole-1,3,4,6-tetraoties, substituted in 10-position with saturated and unsaturated side chains, via palladium catalyzed cross-coupling reactions, are described. These compounds call be considered as granulatimide bis-imide analogues. Their inhibitory activity toward Chk1 kinase and their antiproliferative activities in vitro in four tumor cell lines are reported. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.01.030

文献信息

• Deaminative Reductive Cross-Electrophile Couplings of Alkylpyridinium Salts and Aryl Bromides
  作者：Jennie Liao、Corey H. Basch、Megan E. Hoerrner、Michael R. Talley、Brian P. Boscoe、Joseph W. Tucker、Michelle R. Garnsey、Mary P. Watson

  DOI：10.1021/acs.orglett.9b01014

  日期：2019.4.19

  A nickel-catalyzed reductive cross-coupling of alkylpyridinium salts and aryl bromides has been developed using Mn as the reductant. Both primary and secondary alkylpyridinium salts can be used, and high functional group and heterocycle tolerance is observed, including for protic groups. Mechanistic studies indicate the formation of an alkyl radical, and controlling its fate was key to the success

  使用锰作为还原剂，已经开发了烷基吡啶鎓盐和芳基溴化物的镍催化的还原交叉偶联。伯和仲烷基吡啶鎓盐都可以使用，并且观察到高官能团和杂环耐受性，包括对于质子基团。机理研究表明烷基的形成，控制其命运是该反应成功的关键。
• Neuroprotective and anti-proliferative compounds
  申请人：——

  公开号：US20040102467A1

  公开（公告）日：2004-05-27

  This invention features ring-substituted pyrrolo-&bgr;-carboline derivatives and ring-substitution and structural derivatives of 3-(1H-indol-3-yl)-1H-pyrrole-2,5-dione of formulas (I-III), which are useful as neuroprotective and anti-proliferative compounds. Also disclosed are methods for the preparation of these compounds, selected biological profiles and uses of these compounds in the treatment of various neurodegenerative and inflammatory diseases of the human nervous system and in the treatment of various other proliferative disorders characterized by loss of growth or cellular differentiation control including, but not limited to, cancer and inflammation. 1

  这项发明涉及环取代吡咯β-咔啉衍生物和3-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮的环取代和结构衍生物，其作为神经保护和抗增殖化合物具有用途。还公开了这些化合物的制备方法，选择的生物学特性以及这些化合物在治疗人类神经系统的各种神经退行性和炎症性疾病以及治疗其他各种增殖性疾病中的用途，这些疾病的特征是失去生长或细胞分化控制，包括但不限于癌症和炎症。
• 5-HT-1D receptor ligands
  申请人：Allelix Biopharmaceuticals, Inc.

  公开号：US05504101A1

  公开（公告）日：1996-04-02

  Described herein are tryptamine analogs that display high binding affinity and selectivity for the 5-HT1D.beta. receptor, of the formula: ##STR1## wherein R.sup.1 is a group selected from aryl-C.sub.1-7 alkyl; aryl-C.sub.2-7 alkoxy; aryl-C.sub.2-7 alkanoyl and aryl-C.sub.1-7 alkanoyloxy, wherein said alkyl, alkoxy, alkanoyl and alkanoyloxy groups are optionally substituted by a C.sub.1-4 alkyl substituent and wherein said aryl group is optionally substituted by one or more substituent selected from hydroxyl, halogen, mercapto, linear or branched C.sub.1-4 alkyl, linear or branched C.sub.1-4 alkoxy, linear or branched C.sub.1-4 alkylthio, thiol substituted C.sub.1-4 alkyl and nitro substituted C.sub.1-4 alkyl; R.sup.2 and R.sup.3 are selected independently from H and C.sub.1-4 alkyl; and R.sup.4 is selected from H, C.sub.1-4 alkyl, aryl and arylC.sub.1-4 alkyl. The compounds are useful as reagents for receptor identification and in receptor-based drug screening programs, and can also be used therapeutically to treat conditions for which administration of a 5-HT1D ligand is indicated, for example in the treatment of migraine.

  本文描述了一种具有高结合亲和力和5-HT1D.beta.受体选择性的色胺类似物，其化学式为：##STR1##其中R.sup.1是从芳基-C.sub.1-7烷基；芳基-C.sub.2-7烷氧基；芳基-C.sub.2-7烷酰基和芳基-C.sub.1-7烷酰氧基中选择的基团，其中所述的烷基，烷氧基，烷酰基和烷酰氧基基团可以被C.sub.1-4烷基取代，所述的芳基基团可以被一个或多个取代基所取代，所述取代基是羟基，卤素，巯基，线性或支链C.sub.1-4烷基，线性或支链C.sub.1-4烷氧基，线性或支链C.sub.1-4烷硫基，硫醇取代的C.sub.1-4烷基和硝基取代的C.sub.1-4烷基；R.sup.2和R.sup.3分别选择自H和C.sub.1-4烷基；R.sup.4选择自H，C.sub.1-4烷基，芳基和芳基C.sub.1-4烷基。这些化合物可用作受体识别试剂和受体基药物筛选计划，并且还可用于治疗需要给予5-HT1D配体的情况，例如治疗偏头痛。
• Gold-Catalyzed C(sp³)–C(sp²) Suzuki–Miyaura Coupling Reaction
  作者：Wenqian Du、Fen Zhao、Rongjie Yang、Zhonghua Xia

  DOI：10.1021/acs.orglett.4c00755

  日期：2024.4.19

  gold-catalyzed C(sp3)–C(sp2) Suzuki–Miyaura coupling reaction facilitated by ligand-enabled Au(I)/Au(III) redox catalysis was developed. The cross-coupling of alkyl organometallics was first realized in the redox catalytic cycle in gold chemistry, without the use of external oxidants. This gold-catalyzed C(sp3)–C(sp2) coupling reaction allows a variety of alkyl chain and useful methyl trifluoroborates to react

  开发了一种由配体支持的 Au(I)/Au(III) 氧化还原催化促进的金催化 C(sp 3 )–C(sp 2 ) Suzuki-Miyaura 偶联反应。烷基有机金属的交叉偶联首先在金化学的氧化还原催化循环中实现，无需使用外部氧化剂。这种金催化的 C(sp 3 )–C(sp 2 ) 偶联反应允许各种烷基链和有用的三氟硼酸甲酯在非常温和的条件下与芳基和乙烯基碘化物反应，这为具有挑战性的与烷基的偶联提供了一种新的反应模式有机金属化合物。
• Hong, Seoung-Soo; Dukat, Malgorzata; Teitler, Milt, Medicinal Chemistry Research, 1995, vol. 5, # 9, p. 690 - 699
  作者：Hong, Seoung-Soo、Dukat, Malgorzata、Teitler, Milt、Herrick-Davis, Kathy、McCallum, Kirk、et al.

  DOI：——

  日期：——